تداخلات ريتليسيتينيب

Additionally, concomitant use of ORENCIA with other biologic RA/PsA therapy or JAK inhibitors is not recommended. (نشرة أباتاسبت، التحذيرات والاحتياطات)

• Higher rate of all-cause mortality, including sudden cardiovascular death with another Janus kinase inhibitor (JAK) vs. TNF blockers in rheumatoid arthritis (RA) patients. (نشرة ريتليسيتينيب، تحذير مؤطر)

• Certain CYP3A inducers: Coadministration with strong inducers of CYP3A is not recommended. (نشرة ريتليسيتينيب، التداخلات الدوائية)

• Higher rate of all-cause mortality, including sudden cardiovascular death with another Janus kinase inhibitor (JAK) vs. TNF blockers in rheumatoid arthritis (RA) patients. (نشرة ريتليسيتينيب، تحذير مؤطر)

• Certain CYP3A inducers: Coadministration with strong inducers of CYP3A is not recommended. (نشرة ريتليسيتينيب، التداخلات الدوائية)

• Certain CYP3A inducers: Coadministration with strong inducers of CYP3A is not recommended. (نشرة ريتليسيتينيب، التداخلات الدوائية)

• Higher rate of all-cause mortality, including sudden cardiovascular death with another Janus kinase inhibitor (JAK) vs. TNF blockers in rheumatoid arthritis (RA) patients. (نشرة ريتليسيتينيب، تحذير مؤطر)

• Higher rate of all-cause mortality, including sudden cardiovascular death with another Janus kinase inhibitor (JAK) vs. TNF blockers in rheumatoid arthritis (RA) patients. (نشرة ريتليسيتينيب، تحذير مؤطر)

• Certain CYP3A inducers: Coadministration with strong inducers of CYP3A is not recommended. (نشرة ريتليسيتينيب، التداخلات الدوائية)

• Higher rate of all-cause mortality, including sudden cardiovascular death with another Janus kinase inhibitor (JAK) vs. TNF blockers in rheumatoid arthritis (RA) patients. (نشرة ريتليسيتينيب، تحذير مؤطر)

• Certain CYP3A inducers: Coadministration with strong inducers of CYP3A is not recommended. (نشرة ريتليسيتينيب، التداخلات الدوائية)

Immunosuppressants Everolimus Sirolimus Temsirolimus (IV) Not recommended during and 2 weeks after TOLSURA treatment. (نشرة إيتراكونازول، التداخلات الدوائية)

• Certain CYP3A inducers: Coadministration with strong inducers of CYP3A is not recommended. (نشرة ريتليسيتينيب، التداخلات الدوائية)

• Certain CYP3A inducers: Coadministration with strong inducers of CYP3A is not recommended. (نشرة ريتليسيتينيب، التداخلات الدوائية)

• Higher rate of all-cause mortality, including sudden cardiovascular death with another Janus kinase inhibitor (JAK) vs. TNF blockers in rheumatoid arthritis (RA) patients. (نشرة ريتليسيتينيب، تحذير مؤطر)

• Certain CYP3A inducers: Coadministration with strong inducers of CYP3A is not recommended. (نشرة ريتليسيتينيب، التداخلات الدوائية)

• Certain CYP3A inducers: Coadministration with strong inducers of CYP3A is not recommended. (نشرة ريتليسيتينيب، التداخلات الدوائية)

…IN TRANSPLANT PATIENTS; AND INCREASED MORTALITY IN FEMALE LIVER TRANSPLANT PATIENTS • Increased risk for developing serious infections and malignancies with ASTAGRAF XL ® or other immunosuppressants that may lead to hospitalization or death. [see Warnings and Precautions ( 5.1 , 5.2 )] • Increased mortality in female liver transplant patients with ASTAGRAF XL. (نشرة تاكروليموس، تحذير مؤطر)

• Certain CYP3A inducers: Coadministration with strong inducers of CYP3A is not recommended. (نشرة ريتليسيتينيب، التداخلات الدوائية)

• Higher rate of all-cause mortality, including sudden cardiovascular death with another Janus kinase inhibitor (JAK) vs. TNF blockers in rheumatoid arthritis (RA) patients. (نشرة ريتليسيتينيب، تحذير مؤطر)

Immunosuppressant/neoplastic: everolimus Co-administration of everolimus and PREZISTA/ritonavir is not recommended. irinotecan Discontinue PREZISTA/ritonavir at least 1 week prior to starting irinotecan therapy. (نشرة دارونافير، التداخلات الدوائية)

• Certain CYP3A inducers: Coadministration with strong inducers of CYP3A is not recommended. (نشرة ريتليسيتينيب، التداخلات الدوائية)

• Certain CYP3A inducers: Coadministration with strong inducers of CYP3A is not recommended. (نشرة ريتليسيتينيب، التداخلات الدوائية)

• Higher rate of all-cause mortality, including sudden cardiovascular death with another Janus kinase inhibitor (JAK) vs. TNF blockers in rheumatoid arthritis (RA) patients. (نشرة ريتليسيتينيب، تحذير مؤطر)

• Certain CYP3A inducers: Coadministration with strong inducers of CYP3A is not recommended. (نشرة ريتليسيتينيب، التداخلات الدوائية)

• Certain CYP3A inducers: Coadministration with strong inducers of CYP3A is not recommended. (نشرة ريتليسيتينيب، التداخلات الدوائية)

• Certain CYP3A inducers: Coadministration with strong inducers of CYP3A is not recommended. (نشرة ريتليسيتينيب، التداخلات الدوائية)

• Certain CYP3A inducers: Coadministration with strong inducers of CYP3A is not recommended. (نشرة ريتليسيتينيب، التداخلات الدوائية)

• Certain CYP3A inducers: Coadministration with strong inducers of CYP3A is not recommended. (نشرة ريتليسيتينيب، التداخلات الدوائية)

In kidney, liver, and heart transplant patients Neoral may be administered with other immunosuppressive agents. (نشرة سيكلوسبورين، تحذير مؤطر)

• Certain CYP3A inducers: Coadministration with strong inducers of CYP3A is not recommended. (نشرة ريتليسيتينيب، التداخلات الدوائية)

• Certain CYP3A inducers: Coadministration with strong inducers of CYP3A is not recommended. (نشرة ريتليسيتينيب، التداخلات الدوائية)

Chicken pox and measles, for example, can have a more serious or even fatal course in children on immunosuppressant corticosteroids. (نشرة فلودروكورتيزون، التحذيرات)

Persons who are on immunosuppressant doses of corticosteroids should be warned to avoid exposure to chickenpox or measles. (نشرة فلونيسوليد، الاحتياطات)

• Certain CYP3A inducers: Coadministration with strong inducers of CYP3A is not recommended. (نشرة ريتليسيتينيب، التداخلات الدوائية)

• Certain CYP3A inducers: Coadministration with strong inducers of CYP3A is not recommended. (نشرة ريتليسيتينيب، التداخلات الدوائية)

• Certain CYP3A inducers: Coadministration with strong inducers of CYP3A is not recommended. (نشرة ريتليسيتينيب، التداخلات الدوائية)

• Certain CYP3A inducers: Coadministration with strong inducers of CYP3A is not recommended. (نشرة ريتليسيتينيب، التداخلات الدوائية)

About 13 percent of the cases of neutropenia have ended fatally, but almost all fatalities were in patients with serious illness, having collagen vascular disease, renal failure, heart failure or immunosuppressant therapy, or a combination of these complicating factors. (نشرة كابتوبريل، التحذيرات)

• Certain CYP3A inducers: Coadministration with strong inducers of CYP3A is not recommended. (نشرة ريتليسيتينيب، التداخلات الدوائية)

Prevention or Management Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. (نشرة كلادريبين، التداخلات الدوائية)

• Certain CYP3A inducers: Coadministration with strong inducers of CYP3A is not recommended. (نشرة ريتليسيتينيب، التداخلات الدوائية)

• Certain CYP3A inducers: Coadministration with strong inducers of CYP3A is not recommended. (نشرة ريتليسيتينيب، التداخلات الدوائية)

• Certain CYP3A inducers: Coadministration with strong inducers of CYP3A is not recommended. (نشرة ريتليسيتينيب، التداخلات الدوائية)

• Certain CYP3A inducers: Coadministration with strong inducers of CYP3A is not recommended. (نشرة ريتليسيتينيب، التداخلات الدوائية)

• Certain CYP3A inducers: Coadministration with strong inducers of CYP3A is not recommended. (نشرة ريتليسيتينيب، التداخلات الدوائية)

• Certain CYP3A inducers: Coadministration with strong inducers of CYP3A is not recommended. (نشرة ريتليسيتينيب، التداخلات الدوائية)

• Certain CYP3A inducers: Coadministration with strong inducers of CYP3A is not recommended. (نشرة ريتليسيتينيب، التداخلات الدوائية)

…methylergonovine • HMG-CoA reductase inhibitors: lovastatin, simvastatin (these drugs can be temporarily discontinued to allow PAXLOVID use [see Table 2 , Drug Interactions (7.3) ] ) • Immunosuppressants: voclosporin • Microsomal triglyceride transfer protein inhibitor: lomitapide • Migraine medications: eletriptan, ubrogepant • Mineralocorticoid receptor antagonists:… (نشرة نيرماتريلفير وريتونافير، موانع الاستعمال)

• Certain CYP3A inducers: Coadministration with strong inducers of CYP3A is not recommended. (نشرة ريتليسيتينيب، التداخلات الدوائية)

Immunosuppressants: cyclosporine, sirolimus, tacrolimus ↑ immunosuppressants Therapeutic concentration monitoring is recommended for these immunosuppressants when coadministered with REYATAZ. (نشرة أتازانافير، التداخلات الدوائية)

In this study, current or past smokers had an additional increased risk of overall malignancies. (نشرة ريتليسيتينيب، التحذيرات والاحتياطات)

Immuno-suppressants: e.g., cyclosporine (CsA) sirolimus tacrolimus ↑ immuno-suppressants ↑ elvitegravir (with CsA) ↑ cobicistat (with CsA) Therapeutic monitoring of the immunosuppressive agents is recommended upon coadministration with GENVOYA. (نشرة إلفيتيغرافير وكوبيسيستات وإمتريسيتابين وتينوفوفير، التداخلات الدوائية)

Immunosuppressants Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (نشرة أملوديبين، التداخلات الدوائية)

Impact of Amlodipine on Other Drugs Immunosuppressants Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (نشرة أملوديبين وأتورفاستاتين، التداخلات الدوائية)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (نشرة أملوديبين وأولميسارتان، التداخلات الدوائية)

Immunosuppressants Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when coadministered. (نشرة أملوديبين وفالسارتان، التداخلات الدوائية)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (نشرة أولميسارتان وأملوديبين وهيدروكلوروثيازيد، التداخلات الدوائية)

Treatment has consisted of high doses of corticosteroids alone or, in some cases, concomitantly with an immunosuppressant. (نشرة بنسيلامين، التحذيرات)

Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (نشرة بينداموستين، التحذيرات والاحتياطات)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (نشرة تيمسيروليموس، التحذيرات والاحتياطات)

Cyclosporine, tacrolimus: Monitor for toxicities of these immunosuppressive drugs ( 7.1 ) (نشرة تينيدازول، التداخلات الدوائية)

Frequent PT/INR determinations are advisable until it has been definitely determined that the PT/INR has stabilized Immunosuppressants Clinical Impact: Immunosuppressants such as cyclosporine and tacrolimus can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine, and because renal excretion is the primary elimination route… (نشرة حمض الفينوفيبريك، التداخلات الدوائية)

Therapeutic drug monitoring is recommended with concomitant use Immunosuppressant /neoplastic: everolimus ↑ immunosuppressants Co-administration of everolimus and PREZCOBIX or PREZCOBIX PED is not recommended. irinotecan Discontinue PREZCOBIX or PREZCOBIX PED at least 1 week prior to starting irinotecan therapy. (نشرة دارونافير وكوبيسيستات، التداخلات الدوائية)

Other risk factors for the development of ONJ include immunosuppressive therapy, treatment with angiogenesis inhibitors, systemic corticosteroids, diabetes, and gingival infections. (نشرة دينوسوماب، التحذيرات والاحتياطات)

HBV reactivation has also been reported in patients receiving certain immunosuppressant or chemotherapeutic agents; the risk of HBV reactivation associated with treatment with HCV direct-acting antivirals may be increased in these patients. (نشرة سوفوسبوفير وفيلباتاسفير، التحذيرات والاحتياطات)

Immunosuppressants: Cyclosporine, tacrolimus, sirolimus ↑ Immunosuppressants Therapeutic concentration monitoring is recommended for immunosuppressant agents. (نشرة فوسامبرينافير، التداخلات الدوائية)

Immunosuppressants Clinical Impact: Immunosuppressants such as cyclosporine and tacrolimus can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine, and because renal excretion is the primary elimination route of fibrate drugs including fenofibrate, there is a risk that an interaction will lead to deterioration of renal… (نشرة فينوفيبرات، التداخلات الدوائية)

Immunosuppressants everolimus, rapamycin (also known as sirolimus), temsirolimus budesonide, ciclesonide, cyclosporine, dexamethasone, fluticasone, methylprednisolone, tacrolimus Rapamycin (sirolimus): Ketoconazole tablets 200 mg daily for 10 days increased the C max and AUC of a single 5 mg dose of sirolimus by 4.3 fold and 10.9 fold, respectively in 23 healthy… (نشرة كيتوكونازول، التداخلات الدوائية)

HBV reactivation has also been reported in patients receiving certain immunosuppressants or chemotherapeutic agents; the risk of HBV reactivation associated with treatment with HCV direct-acting antivirals may be increased in these patients. (نشرة ليديباسفير وسوفوسبوفير، التحذيرات والاحتياطات)

If used with concomitant methotrexate and/or other potential immunosuppressive agents, chronic monitoring should be monthly. (نشرة ليفلونوميد، التحذيرات والاحتياطات)

A treatment regimen containing multiple immunosuppressants (including thiopurines) should therefore be used with caution as this could lead to lymphoproliferative disorders, some with reported fatalities. (نشرة ميركابتوبورين، التحذيرات والاحتياطات)

Lymphoma and Other Malignancies Patients receiving immunosuppressants, including mycophenolate mofetil, are at increased risk of developing lymphomas and other malignancies, particularly of the skin [see Adverse Reactions ( 6.1 )]. (نشرة ميكوفينولات، التحذيرات والاحتياطات)

Immunosuppressive Agents There have been reports of increased blood concentrations of cyclosporine and tacrolimus into toxic ranges when patients received these drugs concomitantly with nefazodone. (نشرة نيفازودون، التداخلات الدوائية)

IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persists despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents. (نشرة أتورفاستاتين، التحذيرات والاحتياطات)

Clinically Significant Interactions Affecting Other Drugs CYP3A Substrates Where Small Concentration Changes May Lead to Serious Adverse Reactions Clinical Impact Ritlecitinib is a CYP3A inhibitor. (نشرة ريتليسيتينيب، التداخلات الدوائية)

Thirty-four patients were treated with corticosteroids and one patient was treated with a non-steroidal immunosuppressant. (نشرة أكسيتينيب، التحذيرات والاحتياطات)

Clinically Significant Interactions Affecting Other Drugs CYP3A Substrates Where Small Concentration Changes May Lead to Serious Adverse Reactions Clinical Impact Ritlecitinib is a CYP3A inhibitor. (نشرة ريتليسيتينيب، التداخلات الدوائية)

Clinically Significant Interactions Affecting Other Drugs CYP3A Substrates Where Small Concentration Changes May Lead to Serious Adverse Reactions Clinical Impact Ritlecitinib is a CYP3A inhibitor. (نشرة ريتليسيتينيب، التداخلات الدوائية)

IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy without significant inflammation; and improvement with immunosuppressive agents. (نشرة إيزيتيميب وسيمفاستاتين، التحذيرات والاحتياطات)

Clinically Significant Interactions Affecting Other Drugs CYP3A Substrates Where Small Concentration Changes May Lead to Serious Adverse Reactions Clinical Impact Ritlecitinib is a CYP3A inhibitor. (نشرة ريتليسيتينيب، التداخلات الدوائية)

Clinically Significant Interactions Affecting Other Drugs CYP3A Substrates Where Small Concentration Changes May Lead to Serious Adverse Reactions Clinical Impact Ritlecitinib is a CYP3A inhibitor. (نشرة ريتليسيتينيب، التداخلات الدوائية)

Clinically Significant Interactions Affecting Other Drugs CYP3A Substrates Where Small Concentration Changes May Lead to Serious Adverse Reactions Clinical Impact Ritlecitinib is a CYP3A inhibitor. (نشرة ريتليسيتينيب، التداخلات الدوائية)

Clinically Significant Interactions Affecting Other Drugs CYP3A Substrates Where Small Concentration Changes May Lead to Serious Adverse Reactions Clinical Impact Ritlecitinib is a CYP3A inhibitor. (نشرة ريتليسيتينيب، التداخلات الدوائية)

IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents. (نشرة برافاستاتين، التحذيرات والاحتياطات)

In some cases, vasculitis resolved/improved with drug discontinuation; however, more severe cases required treatment with additional measures including corticosteroids, immunosuppressant therapy, and plasmapheresis. (نشرة بروبيل ثيوراسيل، التحذيرات)

Clinically Significant Interactions Affecting Other Drugs CYP3A Substrates Where Small Concentration Changes May Lead to Serious Adverse Reactions Clinical Impact Ritlecitinib is a CYP3A inhibitor. (نشرة ريتليسيتينيب، التداخلات الدوائية)

IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents. (نشرة بيتافاستاتين، التحذيرات والاحتياطات)

Clinically Significant Interactions Affecting Other Drugs CYP3A Substrates Where Small Concentration Changes May Lead to Serious Adverse Reactions Clinical Impact Ritlecitinib is a CYP3A inhibitor. (نشرة ريتليسيتينيب، التداخلات الدوائية)

Clinically Significant Interactions Affecting Other Drugs CYP3A Substrates Where Small Concentration Changes May Lead to Serious Adverse Reactions Clinical Impact Ritlecitinib is a CYP3A inhibitor. (نشرة ريتليسيتينيب، التداخلات الدوائية)

Clinically Significant Interactions Affecting Other Drugs CYP3A Substrates Where Small Concentration Changes May Lead to Serious Adverse Reactions Clinical Impact Ritlecitinib is a CYP3A inhibitor. (نشرة ريتليسيتينيب، التداخلات الدوائية)

Clinically Significant Interactions Affecting Other Drugs CYP3A Substrates Where Small Concentration Changes May Lead to Serious Adverse Reactions Clinical Impact Ritlecitinib is a CYP3A inhibitor. (نشرة ريتليسيتينيب، التداخلات الدوائية)

Clinically Significant Interactions Affecting Other Drugs CYP3A Substrates Where Small Concentration Changes May Lead to Serious Adverse Reactions Clinical Impact Ritlecitinib is a CYP3A inhibitor. (نشرة ريتليسيتينيب، التداخلات الدوائية)

IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents. (نشرة روسوفاستاتين، التحذيرات والاحتياطات)

CYP1A2 Substrates Where Small Concentration Changes May Lead to Serious Adverse Reactions Clinical Impact Ritlecitinib is a CYP1A2 inhibitor. (نشرة ريتليسيتينيب، التداخلات الدوائية)

Clinically Significant Interactions Affecting Other Drugs CYP3A Substrates Where Small Concentration Changes May Lead to Serious Adverse Reactions Clinical Impact Ritlecitinib is a CYP3A inhibitor. (نشرة ريتليسيتينيب، التداخلات الدوائية)

CYP1A2 Substrates Where Small Concentration Changes May Lead to Serious Adverse Reactions Clinical Impact Ritlecitinib is a CYP1A2 inhibitor. (نشرة ريتليسيتينيب، التداخلات الدوائية)

IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy without significant inflammation; and improvement with immunosuppressive agents. (نشرة سيمفاستاتين، التحذيرات والاحتياطات)

Clinically Significant Interactions Affecting Other Drugs CYP3A Substrates Where Small Concentration Changes May Lead to Serious Adverse Reactions Clinical Impact Ritlecitinib is a CYP3A inhibitor. (نشرة ريتليسيتينيب، التداخلات الدوائية)

IMNM is characterized by proximal muscle weakness and elevated serum CK, which persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody, muscle biopsy showing necrotizing myopathy, and improvement with immunosuppressive agents. (نشرة فلوفاستاتين، التحذيرات والاحتياطات)

CYP1A2 Substrates Where Small Concentration Changes May Lead to Serious Adverse Reactions Clinical Impact Ritlecitinib is a CYP1A2 inhibitor. (نشرة ريتليسيتينيب، التداخلات الدوائية)

Clinically Significant Interactions Affecting Other Drugs CYP3A Substrates Where Small Concentration Changes May Lead to Serious Adverse Reactions Clinical Impact Ritlecitinib is a CYP3A inhibitor. (نشرة ريتليسيتينيب، التداخلات الدوائية)

Clinically Significant Interactions Affecting Other Drugs CYP3A Substrates Where Small Concentration Changes May Lead to Serious Adverse Reactions Clinical Impact Ritlecitinib is a CYP3A inhibitor. (نشرة ريتليسيتينيب، التداخلات الدوائية)

Clinically Significant Interactions Affecting Other Drugs CYP3A Substrates Where Small Concentration Changes May Lead to Serious Adverse Reactions Clinical Impact Ritlecitinib is a CYP3A inhibitor. (نشرة ريتليسيتينيب، التداخلات الدوائية)

Clinically Significant Interactions Affecting Other Drugs CYP3A Substrates Where Small Concentration Changes May Lead to Serious Adverse Reactions Clinical Impact Ritlecitinib is a CYP3A inhibitor. (نشرة ريتليسيتينيب، التداخلات الدوائية)

CYP1A2 Substrates Where Small Concentration Changes May Lead to Serious Adverse Reactions Clinical Impact Ritlecitinib is a CYP1A2 inhibitor. (نشرة ريتليسيتينيب، التداخلات الدوائية)

CYP1A2 Substrates Where Small Concentration Changes May Lead to Serious Adverse Reactions Clinical Impact Ritlecitinib is a CYP1A2 inhibitor. (نشرة ريتليسيتينيب، التداخلات الدوائية)

Clinically Significant Interactions Affecting Other Drugs CYP3A Substrates Where Small Concentration Changes May Lead to Serious Adverse Reactions Clinical Impact Ritlecitinib is a CYP3A inhibitor. (نشرة ريتليسيتينيب، التداخلات الدوائية)

IMNM is characterized by: proximal muscle weakness and elevated serum creatine kinase, which persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents. (نشرة لوفاستاتين، التحذيرات)

Clinically Significant Interactions Affecting Other Drugs CYP3A Substrates Where Small Concentration Changes May Lead to Serious Adverse Reactions Clinical Impact Ritlecitinib is a CYP3A inhibitor. (نشرة ريتليسيتينيب، التداخلات الدوائية)

In some cases, vasculitis resolved/improved with drug discontinuation; however, more severe cases required treatment with additional measures including corticosteroids, immunosuppressant therapy, and plasmapheresis. (نشرة ميثيمازول، التحذيرات)

Clinically Significant Interactions Affecting Other Drugs CYP3A Substrates Where Small Concentration Changes May Lead to Serious Adverse Reactions Clinical Impact Ritlecitinib is a CYP3A inhibitor. (نشرة ريتليسيتينيب، التداخلات الدوائية)

Clinically Significant Interactions Affecting Other Drugs CYP3A Substrates Where Small Concentration Changes May Lead to Serious Adverse Reactions Clinical Impact Ritlecitinib is a CYP3A inhibitor. (نشرة ريتليسيتينيب، التداخلات الدوائية)

CYP1A2 Substrates Where Small Concentration Changes May Lead to Serious Adverse Reactions Clinical Impact Ritlecitinib is a CYP1A2 inhibitor. (نشرة ريتليسيتينيب، التداخلات الدوائية)

Immunosuppressive Drugs Tacrolimus: Tacrolimus has been shown to be metabolized via the CYP3A system. (نشرة نيفيديبين، الاحتياطات)